Enovis: An Innovation Driven Medical Technology Company

Roadshow Presentation
Forward Looking Statement and Non-GAAP Disclaimer

This document has been prepared by Colfax Corporation, a Delaware corporation ("Colfax"), solely for informational purposes. Upon completion of the intended separation of Colfax’s fabrication technology and specialty medical technology businesses (the “Separation”), Colfax will retain the specialty medical technology business and will change its name to Enovis Corporation (the "Company" or "Enovis"). References herein to the terms “Colfax” and “Enovis,” when used in a historical context, refer to Colfax and its consolidated subsidiaries before giving effect to the Separation and, when used in the future tense, refer to Enovis and its consolidated subsidiaries after giving effect to the Separation.

Forward-Looking Statements

This document includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’s plans, goals, objectives, outlook, expectations and intentions, including the Separation, and the timing, method and anticipated benefits of the Separation and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements, including general risks and uncertainties such as market conditions, economic conditions, geopolitical events, changes in laws, regulations or accounting rules, fluctuations in interest rates, terrorism, wars or conflicts, major health concerns, natural disasters or other disruptions of expected business conditions. Factors that could cause Enovis’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response; material delays and cancellations of medical procedures; supply chain disruptions; the impact on creditworthiness and financial viability of customers; macroeconomic conditions; the war in the Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of the Ukraine; risks relating to the Separation, the uncertainty of obtaining regulatory approvals, Colfax’s ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes, the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all, the ability to realize the anticipated benefits of the Separation, developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of Enovis following the Separation; other impacts on Enovis’s business and ability to execute business continuity plans; and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This document speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Measures

This document includes a presentation of adjusted EBITDA and adjusted EBITDA Margin and other financial measures that are not calculated in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"), which Enovis uses to measure the performance of its business.

• Adjusted EBITDA represents net income (loss) from continuing operations excluding the effect of restructuring and other related charges, European Union Medical Device Regulation ("MDR") and related costs, acquisition-related intangible asset amortization and other non-cash charges, intangible asset impairment charges, strategic transaction costs, pension settlement gains and losses, and debt extinguishment charges, as well as interest expense net, income tax expense (benefit), and depreciation and other amortization. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Further, Enovis presents adjusted EBITDA (and adjusted EBITDA margin) on a segmented and organic/core basis, which is subject to the same adjustments as adjusted EBITDA. Lastly, Enovis presents pro forma adjusted EBITDA which includes the same adjustments above, excludes stock compensation expense, and reflects corporate cost in all periods presented.

• Organic or core sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.

The non-GAAP financial measures provided herein are adjusted for certain items as presented in the Appendix and should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies. Management believes that these non-GAAP financial measures provide useful information to investors by offering additional ways of viewing Enovis’s results. Management also believes that presenting these measures allows investors to view its performance using the same measures that Enovis uses in evaluating its financial and business performance and trends. A reconciliation of adjusted EBITDA and adjusted EBITDA Margin to the closest GAAP financial measure is not available without unreasonable efforts on a forward-looking basis due to the impact and timing on future operating results arising from items excluded from these measures.

No Solicitation, No Offer, Additional Information

This communication shall not constitute an offer for any securities for sale, nor shall there be any offer, safe or distribution of securities in any jurisdiction in which such offer, sale or distribution would be unlawful prior to appropriate registration or qualification under the securities law of such jurisdiction.

For additional information with respect to Colfax and Enovis, please refer to Colfax’s filings with the SEC, and with respect to the Separation, please refer to the registration statement on Form 10 of ESAB Corporation, as it may be further amended, on file with the SEC ("Form 10"). The consummation of the Separation is subject to customary conditions, as further described in the Form 10. The financial information included in this document may not necessarily reflect Enovis’s financial position, results of operations, and cash flows in the future or what Enovis’s financial position results of operations, and cash flows would have been had Enovis been a standalone independent, publicly traded company during the periods presented.

Certain Definitions

As used in this document, references to “DD” mean “double digit,” references to “LDD” mean “low double digit,” references to “HSD” mean “high single-digit” and references to “MSD” mean “mid-single digit.”
Clear Strategy for Shareholder Value Creation

**Strategic Opportunities**

- ✓ Shaping P&R platform for sustained MSD growth
- ✓ Rapidly expanding high-margin, DD growth Recon platform
- ✓ Expanding margins with a clear strategy and EGX
- ✓ Accelerating growth through technology investments and acquisitions

**3-Year Goals**

- HSD
  - Organic Revenue Growth
- ~20%
  - aEBITDA Margin
- $2B+
  - Annual Sales

Compounding value creation from growth, margins, and investment
Strong Global Positions in Attractive Segments

2021 Performance

$1,516mm
PF Sales

$216mm
PF aEBITDA

- **Europe** 27%
- **United States** 68%
- **ROW** 5%

- **P&R** 68%
- **Recon** 32%

Two Attractive Business Segments

**Fast growing reconstructive platform**

- DJO Surgical DD growth engine in US, leading in Shoulder and rapid adoption in Knee & Hip
- Globalized footprint and offering through acquisition of Mathys
- Expansion into attractive Foot & Ankle market in 2021

**Global leader in prevention & recovery (P&R)**

- Global leader in rigid bracing and soft goods
- Reshaping care path with MotionMD® and MotioniQ™ digital solutions
- Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities

Positioned for significant growth and value creation

1. PF sales for full-year revenue contribution from Mathys, Trilliant, and MedShape acquisitions.
2. PF aEBITDA for full-year aEBITDA contribution from Mathys, Trilliant, and MedShape and 2021 legacy Colfax corporate costs allocated to Enovis on an on-going basis. Refer to Appendix for non-GAAP reconciliations.
### Addressing Large, Attractive Ortho Market

Enovis competes in half of the **$53B Orthopedics market** and “touches” nearly all segments. The market growth trends provide runway.

#### Our Recon served markets

<table>
<thead>
<tr>
<th>Segment</th>
<th>Market CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knee</td>
<td>3-4%</td>
</tr>
<tr>
<td>Hip</td>
<td>7-8%</td>
</tr>
<tr>
<td>Extremities</td>
<td>3-4%</td>
</tr>
<tr>
<td>Trauma</td>
<td>3-4%</td>
</tr>
<tr>
<td>Sports Medicine</td>
<td>6-7%</td>
</tr>
<tr>
<td>Spine</td>
<td>3-4%</td>
</tr>
<tr>
<td>Biologics</td>
<td>2-3%</td>
</tr>
</tbody>
</table>

#### Market CAGR

<table>
<thead>
<tr>
<th>Segment</th>
<th>Market CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Implants and Instrumentation</td>
<td>9</td>
</tr>
<tr>
<td>Prevention &amp; Rehabilitation (P&amp;R)</td>
<td>8</td>
</tr>
<tr>
<td>Enovis serves markets</td>
<td></td>
</tr>
<tr>
<td>$58B</td>
<td>$5B ~4%</td>
</tr>
</tbody>
</table>

#### Aging but active population, rising obesity

#### Transitioning to outpatient care

#### Innovation improving the quality of care

Enovis is well-positioned in segments with strong long-term growth drivers.

Uniquely Positioned Across Full Ortho Care Continuum

**PREVENTION**
- Off-loading braces
- Back braces
- Cold therapy

**REPAIR**
- Shoulders
- Knees
- Hips
- Foot/Ankle

**RECOVERY**
- Post-op braces
- Walker boots
- Cold therapy

**PERFORMANCE**
- Athletic braces
- Muscle stimulation

**PREVENTION**
- Off-loading braces
- Back braces
- Cold therapy

**SURGICAL**
- Shoulders
- Knees
- Hips
- Foot/Ankle

**RECOVERY**
- Post-op braces
- Walker boots
- Cold therapy

**REHAB**
- Electrotherapy
- Laser therapy
- Heat/cold therapy
- Traction devices

**STRATEGIC ADVANTAGES**
- Brand leverage with hospitals, surgeons, clinicians, patients
- Digital workflow solutions for clinics
- Connected medicine solutions for patient journey
- Full “episode of care” partner to ambulatory surgery centers (ASC)

Leveraging broad and deep market access and technology for strategic advantage
Enovis’ Attractive Position

- Big enough for healthy margins but additional room to scale
- Small enough to operate like an innovator
- Can select most valuable growth paths
- Ample bolt-on opportunities, attractive path to market/scale for innovators

Enovis is positioned for share gain, scale, and expansion


1. 2021 revenue, as reported.
Our Enovis Growth eXcellence business system is a set of tools, processes, and culture, incorporating continuous improvement to drive and fuel growth.

<table>
<thead>
<tr>
<th>Year</th>
<th>Lean Supply Chain</th>
<th>Agile Growth</th>
<th>Scalable Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2016</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2017</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2018</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2019</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2020</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
<tr>
<td>2021</td>
<td>Safety, Delivery, Productivity</td>
<td>Innovation cadence, Commercial excellence</td>
<td>Insource, Streamline</td>
</tr>
</tbody>
</table>

Above Market
Organic Growth
Productivity Foundation
For Further Margin Expansion

Enovis EGX journey has strong momentum using tools that had big impact at ESAB.
Enovis Evolution to HSD Organic Growth Underway

Above market in Recon

2018

$1.5B

$1.2B

32%

80%

2021

68%

• Operational improvements
• Investments in DD recon engine
• Innovation cadence
• High growth acquisitions

Above market in Recon and P&R

Organic

Growth Underway

Recon

P&R

Scaling top line growth and outperforming the market in Recon and P&R

1. See Appendix for reconciliation of sales pro forma for full-year revenue contribution from Mathys, Trilliant, and MedShape.
Market Leader in Prevention & Recovery with Differentiated Brands

**P&R Sales & Market Position**

$5B market expected to grow 3-4% per year

- **Footcare**
- **Bracing**
- **Recovery Sciences**

- ~$1.0B

**Market Leadership**

- Industry-defining products across Orthopedics
- Leader in fast growing Sports Medicine segment
- MotionMD® workflow software solution drives 45% of US Clinics
- Leader in therapy modalities strengthened by LiteCure™
- Strong International Position: 32% ex-US Sales

**Technology and Brand Leadership**

- DonJoy®
- Aircast®
- EXOS®
- Chattanooga®
- LiteCure®

Industry Leadership

- #1 Globally in Bracing
- #1 Globally in Rehab
- #2 In Bone Stimulation

Attractive leading global positions in bracing and recovery sciences

1. Source: Based on internal Enovis analysis.
P&R Sales Growth Restored to Above Market

**Execution Strategies**

1. Re-establishing customer service levels
2. Increasing vitality
3. Leveraging clinic workflow position and channel strength for share gains

**Historical Organic Sales Growth**

<table>
<thead>
<tr>
<th>Year</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-17</td>
<td>-4%</td>
<td>-2%</td>
<td>0%</td>
<td>3%</td>
<td>6%</td>
<td>-13%</td>
<td>14%</td>
</tr>
<tr>
<td>2018</td>
<td>3%</td>
<td>3%</td>
<td>6%</td>
<td>0%</td>
<td>14%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Adjusted for constant currency, excludes acquisition and discontinued business lines.

2022 Guidance:

**MSD Sales Growth**

- Above market
- Investment and improvements driving sustained above-industry growth
Increased Innovation Driving Core Growth and Accelerating Key Strategies

P&R New Product Introductions

<table>
<thead>
<tr>
<th>From...</th>
<th>To...</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>2021</td>
</tr>
</tbody>
</table>

**Vitality Index**

- 2018: 10
- 2021: 33

**Vitality**

- 2018: 7%
- 2021: 15%

**Market-Leading Innovation**

1. **Modernizing Core segments**
2. **Expanding into high growth categories**
3. **Leading transition to modalities**
4. **Pioneering Connected Medicine MotionIQ™**

**Progress and pipeline innovation to drive quickly to 20%+ vitality goal**

---

1. Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue. Does not include P&R class 3 bone stimulation revenues.
Leading in Digital Healthcare with MotionMD®

SaaS Workflow Automation Software Solution

- Secure. Paperless. Integrated
- 24% Reduction in inventory
- 8% Improvement in collections
- 40% Reduction in Billing lead time

Clinic Location Growth

- +57% in 2021 from 445 in 2017
- 45% share in US clinics / used by over 30K med professionals
- Key driver in large Hospital clinic conversions: $15mm 2020-2021
- MotionMD® revenue delivers 600 bps higher gross margin
- Customer Retention Rate of 99%
- DJO Share of wallet Direct 70% / OfficeCare® 96%

Product Revenue Growth

- +18% in 2021 from $40mm in 2017

Winning with Workflow Solutions

- 2017 to 2021
  - 2017: $40mm
  - 2021: $77mm

A purpose-built SaaS platform creates stickiness and enables share gain
Attractive Reconstructive Segment & Market Position

Revenue Split and Market Growth\(^1\)

\- $20B market segments; Enovis WAMGR of 5-6%

\- Extremities market growing 7-8%

\- Foot & Ankle

\- Other

\- Hip

\- Knee

\- Shoulder

\- ~$0.5B\(^2\) Enovis ‘21 Sales

Attractive Positions

\- ~50% of Recon platform in high growth extremities segments

\- A global leader in Shoulder (Reverse, Stemless anatomic)

\- Sustained share gain in large US Hip/Knee segments

\- Innovative and expanding Foot & Ankle portfolio

\- Deep advanced technology offering across platform

Positioned in fast-growing segments with market-leading innovation

---

1. Source: Based on internal Enovis analysis.
2. 2021 sales pro forma for recent acquisitions (annualized impact vs partial year 2021 sales).
Fast-Growing Recon Business with Proven Playbook

- **2X market growth** led by Altivate Reverse and accelerating Altivate Edge anatomic stemless
- **Proven MatchPoint® pre-operative plan and PSI system** in 35%+ of procedures

Best-in-Class medical education across segments
Unparalleled KOL leadership team
Aggressive NPI cadence

Track record of sustained strong DD growth across segments
Winning in High Growth ASC Segment

Drivers of ASC Growth

• Medicare / Medicaid rule change 1/1/2020
• Shrinking physician fee coverage by CMS → fueling physician interest in ASC ownership
• COVID-19 accelerated move to ASC
• Patient preference for outpatient / ASC care setting

Enovis Advantage

• Enovis continuum of care coverage
• EMPOWR® Knee patient profile
• Sports medicine physicians capturing TKA
• ASC-enabling technologies (Insight, Adaptable +)

Rapid Expansion of Empowr® Knee in ASC

% of DJO Surgical Knee Revenue in ASC

ASC360 Solutions

New high-growth ASC segment favors agile innovator
Targeted Computer Assisted Surgery (CAS) Strategy

*Anatomically distinct*

Suite of offerings uniquely tooled to each anatomy

Match Point System™

Match Point™ System used in ~30% of Enovis shoulder cases

Coming soon

Best-in-class Pre-Op Planning & PSI¹ for Total Ankle

Unique guidance platform leveraging AR

*Spanning entire workflow*

End-to-end set of integrated components that can also be used on a standalone basis

Pre-Op / Patient Specific Instrumentation

Intra-Operative Imaging

Surgical Guidance / Robotics

*Platform purpose-built for ASC*

Optimized for ASC success – effective, efficient and affordable

Low capital costs

Time and Space Efficient

Micro footprint

Enovis CAS technologies will provide a flexible and scalable approach

1. PSI stands for Patient Specific Instrumentation.
Strong Positions in Attractive Foot and Ankle Market

High-Growth, Fragmented Market

* $2B Global Market
  * Ankle: ~250k procedures
  * Hindfoot: ~100k procedures
  * Midfoot: ~150k procedures
  * Forefoot: ~2mm procedures

HSD Market Growth

Acquired Innovative Technologies with Great Outcomes

- **MEDSHAPE**
  - >20% revenue CAGR 2015-19 via unique shape metal fixation
  - Developing technologies to span F&A and Recon
- **TRILLIANT**
  - ~15% revenue CAGR 2015-19
  - Broad portfolio of differentiated plating systems
- **STAR™ Ankle**
  - 20+ years of best-in-class patient outcomes
  - Clear pathway to modernize unique mobile bearing design

Clear Strategy to Grow, Expand and Scale

1. Building strong dedicated channel
2. Developing and acquiring differentiated products for other high-growth procedures
3. Modernizing STAR™ and expanding ankle portfolio
4. Globalize through Mathys

Integration on track, momentum accelerating with clear pathway to $100M DD growth platform

Note: Number of procedures based on US surgical activity.
Globalization of Recon Through Mathys Acquisition

**Strategic Rationale**

- **European orthopedics leader** with an extensive direct sales channel and strong local brand
- **Highly complementary** product technologies
- Unique, proprietary **Ceramys ceramics and RM Pressfit elastic monoblock** technologies
- Hip and Shoulder historical growth @ \(~2x\) market
- Enables **aggressive international rollout** of Altivate® Reverse and Empowr® 3D Knee platforms

**$160mm**

2022 Expected Ex-US Sales

- **Pre-Acquisition**
- **Pro-Forma Reflecting Acquisition**

**Mathys acquisition nearly doubles addressable market and expands portfolio**

---

2. Not including Foot & Ankle ($3B globally).
Realizing the Strategic Benefits from Mathys Acquisition

**Strategic Pillar**

- Expand Mathys Shoulder with Altivate® Reverse
- Strengthen Mathys Knee with Empowr®3D
- Accelerate US Surgical Hip breadth with RM Monoblock & Optimus Stem

**Goals**

- **MSD ➔ HSD / LDD**
  - International Organic Revenue Growth

- **$15mm**
  - Annual Cost Synergies by 2024

**Cross-sell Leading Technologies**

- Create competitive advantage with ceramics in allergy-free implants spanning Recon segments
- Fuel RM Pressfit elastic monoblock beyond Hip
- Develop global CAS offering & outcomes registry

**Globalize Innovation**

- Supply chain optimization, insourcing and productivity
- Scaling the international business

**Drive Productivity**

- Expand Mathys Shoulder with Altivate® Reverse
- Strengthen Mathys Knee with Empowr®3D
- Accelerate US Surgical Hip breadth with RM Monoblock & Optimus Stem

Complementary markets and technologies enable growth acceleration and margin improvement
Recent Portfolio Investments Reshaping Our Business

Entered Foot & Ankle
- $1B Market
- HSD growth category
- Fragmented competition

MedShape® / Trilliant®

AR Surgical Platform
- Next Gen total joint arthroplasty system
- Footprint and cost positioned for ASC

Arvis™ AR

ASC Solutions
- Double digit procedural volume growth
- Provides Surgical assistance

ADAPTABLE®

High Growth Modalities
- HSD growth category
- Synergy opportunities
- Expanded applications

LiteCure™ Laser

Geographical Expansion
- Drives growth outperformance
- Increased scale benefits
- Direct market penetration

MATHYS

Projected 2024 Portfolio Impact
$300mm
Sales
DD+
Organic Growth
Accretive
Gross Margins

Accelerating growth through technology investments and acquisitions
Clear Short-Term Path to 20% aEBITDA Margins

**aEBITDA Margin (%)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Investment</th>
<th>COVID</th>
<th>Acquisitions</th>
<th>SG&amp;A Streamlining</th>
<th>Operating Leverage</th>
<th>Acquisitions</th>
<th>COVID Recovery</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>18.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>14.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2024E</td>
<td>~20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Margin Drivers**

- Fast growth + high gross margins creating powerful operating leverage
- Acquisitions creating additional opportunities for scaling and cost synergies (e.g., $15mm at Mathys)
- Actions underway to streamline and remove $20mm of cost by 2024
- COVID introduced >$20mm of supply chain challenges and inflation that can be recovered as pressures subside
- Driving price in P&R to mitigate inflation impacts
- Investing to support in-sourcing and other productivity projects

Continuous margin improvement through EGX with longer-term headroom to 25%+

Note: Bridging bars from 2021 to 2024 are directional and not to scale; refer to Appendix for non-GAAP reconciliations. 2018 results are based on management’s internal reports.
Forecasting Strong Sales & Profit Growth in 2022

### 2022 Forecast

**10-14% revenue growth**
- 6-9% organic; (1%) FX
- ~$1.6B total revenue

**$245-265mm aEBITDA**
- ~16% reported margins
- ~17% core (ex-acq.) margins
- +150-200 bps yr-yr incl. 80+ bps from lower corporate costs
- $45-48mm Q1 aEBITDA

### Key Assumptions

- Outperform markets with DD organic growth in Recon, healthy MSD growth in P&R
- Revenue follows typical seasonality + COVID recovery to deliver revenue pattern of ~47-48% in 1H (~23% in Q1) and ~52-53% in H2 (Q4 is strongest quarter)

- Significant revenue growth and productivity initiatives support margin expansion
- COVID-driven inefficiencies and inflation begin to moderate in Q3/Q4
- Corporate costs drop ~$15mm with path for additional efficiencies
- Streamlining project underway with ~$10mm of run-rate savings by yr-end
- aEPS guidance assumes pro forma capital structure post-monetization of ESAB retained stake
- CapEx supports growth, insourcing and Mathys integration

---

1. Assumes 1:3 reverse share split.

---

Expect $2.20-$2.40 of adjusted EPS\(^1\) in FY 2022
Ample Resources to Support Growth

**Strong Balance Sheet**

* < 1.5x Net Leverage at separation

10% Retained Stake in ESAB to be exchanged for debt within 12 months of separation, expected to create a net cash position*

$900mm initial 5-year revolving credit facility to support strategic growth needs

**Growing FCF ($mm)**

- Effective processes across the company to deliver cash flow commitments, balanced with growth objectives
- Disciplined prioritization of capital to support business growth productivity
- Proven acquisition program that secures key value drivers and drives attractive returns

Strong balance sheet provides flexibility and investment firepower
Realizing Our Vision – High-Value MedTech Growth Company

Enovis Sales Performance & Goals

Clear path to $2B and beyond with HSD organic growth and expanded margin profile

1. See Appendix for reconciliation of pro forma sales.
Appendix
Strong Leadership Team, Deep MedTech Experience

Board of Directors

- Mitch Rales, Chairman, Colfax, Danaher Co-Founder
- Matt Trerotola, CEO
- Brady Shirley, President & COO
- Barbara Bodem, Former SVP & CFO of Hillrom
- Liam Kelly, CEO of Teleflex Incorporated
- Angie Lalor, Former SVP of HR, Danaher, 3M
- Phil Okala, COO, UPenn Health Systems
- Christine Ortiz, Prof. of Materials Sciences and Engineering, MIT
- Clay Perfall, Operating Executive, Tailwind Capital
- Rajiv Vinnakota, President, Institute for Citizens & Scholars
- Sharon Wienbar, Former Partner, Scale Venture Partners

Enovis Senior Leadership Team

- Matt Trerotola, CEO
- Brady Shirley, President & COO
- Chris Hix, EVP & CFO
- Dan Pryor, EVP BD, Strategy
- Patty Lang, CHRO
- Brad Tandy, General Counsel

Senior leaders with over 80 years of combined MedTech experience

1. Joining Board upon consummation of separation.
Continuum of Care in Practice

Illustrative Osteoarthritic (OA) Patient Journeys

**PREVENTION**
- **Performance**
  - Shoulder OA with restricted ROM
  - Weekend Warrior with Knee OA
  - Active patient with Ankle OA

- **Prevention / Conservative Care**
  - Fitted for shoulder support
  - HP Laser Therapy

- **Surgical Intervention**
  - Altivate® Reverse Shoulder in ASC
  - EMPOWR® 3DKnee Replacement in ASC

- **Recovery**
  - Post-Op Shoulder Immobilizer
  - Cold Therapy

- **Rehab**
  - HP Laser Therapy

**REPAIR**
- **Surgical Intervention**
  - HP Laser Therapy
  - Cold Therapy

**RECOVERY**
- **Recovery**
  - X4 Post-Op Smart Brace
  - Laser Therapy

**Connected care beginning at initial interaction**

Enovis is the only player with true start-to-end engagement across the continuum
Digital Strategies Span Orthopedic Care Continuum

Clinic / ASC Workflows

Surgical Workflows

Patient Workflows

PREVENTION

Performance

Prevention / Conservative Care

Surgical Intervention

Recovery

Rehab

Purpose-built SaaS platform for multiple value-added services

Multi-pronged, anatomically-specific CAS product suite

Connected medicine platform across post-op outpatient rehab

Creating unique advantages today, breakthrough potential in the future
Pioneering Connected Medicine with MotioniQ™

Ultimate Wearable Technology

- **SmartBrace™** transforming “in-protocol” brace into wearable technology
- Enables Post-Op remote patient monitoring across patient journey
- Opens broader outcomes data collection in linked collaboration with CAS Pre-Op/Intra-Op technologies
- DJO leveraging global bracing leadership, continuum breadth and large installed base of MotionMD® in ~45%+ of US ortho clinics

Enable doctors and patients to virtually walk side-by-side throughout the care continuum
**Prevention and Recovery Markets with Steady MSD Growth**

<table>
<thead>
<tr>
<th>Segment</th>
<th>Key Demand Drivers</th>
<th>Growth in Procedure Volume&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Trends Driving Innovation</th>
</tr>
</thead>
<tbody>
<tr>
<td>JOINT RECONSTRUCTION</td>
<td>• Osteoarthritis prevalence</td>
<td>5-6%</td>
<td>• Inpatient to outpatient across patient journey</td>
</tr>
<tr>
<td></td>
<td>• Diabetes prevalence</td>
<td></td>
<td>• Conservative care expansion</td>
</tr>
<tr>
<td>SPORTS MEDICINE</td>
<td>• Active lifestyles</td>
<td>~6%</td>
<td>• Outpatient to home rehab</td>
</tr>
<tr>
<td>TRAUMA AND INJURY</td>
<td>• GDP growth</td>
<td>~3%</td>
<td>• Alternatives to traditional pain management (opioid)</td>
</tr>
<tr>
<td></td>
<td>• Mobility</td>
<td></td>
<td>• Clinic consolidation into hospitals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Growth in modality therapeutics (e.g., HP laser)</td>
</tr>
</tbody>
</table>

*Volume WAMGR: ~5%*

Diverse global market with 3-4% projected revenue growth driven by long-term trends

---

<sup>1.</sup> Source: Internal management estimates and SmartTrak (by BioMedGPS, LLC) projections for procedure growth in 2023 and beyond.
## Recon Double-Digit Organic Growth Projection

<table>
<thead>
<tr>
<th>% of Recon</th>
<th>Market Growth</th>
<th>Projected Growth vs. Market</th>
<th>2022+ Growth Projection</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Shoulder</td>
<td>~30%</td>
<td>7-8%</td>
<td>~2x</td>
</tr>
<tr>
<td>US Hip / Knee</td>
<td>~30%</td>
<td>3-4%</td>
<td>3-5x</td>
</tr>
<tr>
<td>Foot / Ankle</td>
<td>~10%</td>
<td>6-7%</td>
<td>2-3x</td>
</tr>
<tr>
<td>Int’l Recon</td>
<td>~30%</td>
<td>4-5%</td>
<td>2-3x</td>
</tr>
</tbody>
</table>

Clear track record and trajectory for sustained double-digit organic growth

---

Broad Range of Opportunities to Accelerate by Acquisition

**Expand**
Redefine boundaries

- Expand along Continuum of Care
- Enter Logical Clinic-Based Adjacencies
- Apply Technology in Other Markets

**Extend**
Build out from core

- Expand Geographically
- Add High-Growth / High-Margin P&R
- Build around Healthcare Provider
- Enter High-Growth Recon Sub-Segments

**Excel**
Win in the core

- Fill Product Line Gaps
- Add Digital Solutions
- Expand Channels

**Acquisition Criteria**

- Fuels growth
- Improves gross margin
- Accelerates strategy
- Expands market reach
- Creates scale
Strong Growth Outlook

**Sales ($B)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>2%</td>
<td></td>
<td></td>
<td></td>
<td>2%</td>
</tr>
<tr>
<td>2019</td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td>4%</td>
</tr>
<tr>
<td>2020</td>
<td>(11)%</td>
<td></td>
<td></td>
<td></td>
<td>(11)%</td>
</tr>
<tr>
<td>2021</td>
<td>14%</td>
<td></td>
<td></td>
<td></td>
<td>14%</td>
</tr>
<tr>
<td>2022E</td>
<td>6-9%</td>
<td></td>
<td></td>
<td></td>
<td>6-9%</td>
</tr>
<tr>
<td>2024E</td>
<td>10-14%</td>
<td></td>
<td></td>
<td></td>
<td>10-14%</td>
</tr>
</tbody>
</table>

**Investing in faster-growing segments**
- Acq’ed by Colfax

**Strengthening innovation**

**Improving ops / customer service**

**Accelerating Growth**

- Supply chain investment and EGX improvements restored P&R growth in 2H 2019
- Innovation engine investments contributing to higher organic growth across the company
- Acquisitions into faster-growing market segments accelerating growth
- Ramping investments in commercial capabilities
- Expecting to continue to outgrow our markets in 2022 and beyond

Refer to Appendix for non-GAAP reconciliations, 2018 organic growth based on management’s internal reports. 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019.
Converting Growth into Margin Expansion

aEBITDA Margin (%)

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>18.4%</td>
</tr>
<tr>
<td>2019</td>
<td>17.9%</td>
</tr>
<tr>
<td>2020</td>
<td>13.7%</td>
</tr>
<tr>
<td>2021</td>
<td>14.5%</td>
</tr>
<tr>
<td>2022E</td>
<td>~17% excl. acq.</td>
</tr>
<tr>
<td>2024E</td>
<td>~20%</td>
</tr>
</tbody>
</table>

Margin Drivers

- Fast growth + high gross margins creating powerful operating leverage
- Acquisitions creating additional opportunities for scaling and cost synergies (e.g., $15mm at Mathys)
- Actions underway to streamline and remove $20mm of cost by 2024
- COVID introduced >$20mm of supply chain challenges and inflation that can be recovered as pressures subside
- Driving price in P&R to mitigate inflation impacts
- Investing to support in-sourcing and other productivity projects

Note: 2022 includes approximately $60mm of annual pro forma costs representing the legacy Colfax corporate costs, and $73mm for the period 2018-2021. 2019 aEBITDA margin is pro-forma for pre-acquisition results. 2018 aEBITDA margin is based on management’s internal reports. Refer to Appendix for non-GAAP reconciliations.
2021 - 2019 Enovis Recon Performance vs Peers

2021 vs 2019 Organic Growth

7%  
-3%

Recon Peers Avg. Relevant Growth

1. Growth on a sales per day basis.
### Segment-Level Performance

**Quarterly Sales (2019 – 2021)**

<table>
<thead>
<tr>
<th>Segment Level</th>
<th>Sales (Q1)</th>
<th>Sales (Q2)</th>
<th>Sales (Q3)</th>
<th>Sales (Q4)</th>
<th>Sales (FY)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention &amp; Recovery</strong></td>
<td>235</td>
<td>267</td>
<td>256</td>
<td>268</td>
<td>1,026</td>
</tr>
<tr>
<td><strong>Reconstructive</strong></td>
<td>76</td>
<td>89</td>
<td>104</td>
<td>131</td>
<td>400</td>
</tr>
<tr>
<td><strong>Total Enovis</strong></td>
<td>311</td>
<td>356</td>
<td>360</td>
<td>399</td>
<td>1,426</td>
</tr>
</tbody>
</table>

**Segment level aEBITDA % of Sales (2021)**

<table>
<thead>
<tr>
<th>Segment Level</th>
<th>aEBITDA %</th>
<th>Q1 %</th>
<th>Q2 %</th>
<th>Q3 %</th>
<th>Q4 %</th>
<th>FY %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention &amp; Recovery</strong></td>
<td>9.4%</td>
<td>12.5%</td>
<td>15.8%</td>
<td>14.4%</td>
<td>13.1%</td>
<td></td>
</tr>
<tr>
<td><strong>Reconstructive</strong></td>
<td>21.2%</td>
<td>19.1%</td>
<td>15.0%</td>
<td>17.5%</td>
<td>17.9%</td>
<td></td>
</tr>
<tr>
<td><strong>Total Enovis</strong></td>
<td>12.3%</td>
<td>14.1%</td>
<td>15.6%</td>
<td>15.5%</td>
<td>14.5%</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Dollars in millions. Some periods may not foot due to rounding.
Supplemental 2022 Guidance Information

Depreciation expense: ~$80mm

CapEx spend: $100-110mm

Tax rate: Mid-20%

Share-based comp. expense ~$27mm
Non-GAAP Reconciliation

$ millions

<table>
<thead>
<tr>
<th>Component of Change</th>
<th>First Quarter</th>
<th>Second Quarter</th>
<th>Third Quarter</th>
<th>Fourth Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enovis Pro Forma(1)</td>
<td>$1,292.7</td>
<td>$315.9</td>
<td>$297.3</td>
<td>$339.7</td>
</tr>
<tr>
<td>$288.4</td>
<td>$307.1</td>
<td>$295.8</td>
<td>$310.6</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component of change</th>
<th>$</th>
<th>%</th>
<th>$</th>
<th>%</th>
<th>$</th>
<th>%</th>
<th>$</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing businesses(2)</td>
<td>4.8</td>
<td>1.5%</td>
<td>10.6</td>
<td>3.5%</td>
<td>18.8</td>
<td>4.5%</td>
<td>24.1</td>
<td>7.8%</td>
</tr>
<tr>
<td>Acquisitions(3)</td>
<td>5.4</td>
<td>1.9%</td>
<td>3.1</td>
<td>1.0%</td>
<td>1.1</td>
<td>0.4%</td>
<td>1.1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Foreign currency translation(4)</td>
<td>(5.4)</td>
<td>-1.9%</td>
<td>(4.9)</td>
<td>-1.6%</td>
<td>(2.9)</td>
<td>-1.0%</td>
<td>(2.1)</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Components of change</td>
<td>4.8</td>
<td>1.5%</td>
<td>8.8</td>
<td>2.9%</td>
<td>11.5</td>
<td>3.5%</td>
<td>23.1</td>
<td>7.5%</td>
</tr>
</tbody>
</table>

Note: Dollars in millions. Some periods may not foot due to rounding.

(1) Enovis pro forma Net sales and sales components for the year ended December 31, 2019 include Medical Technology segment sales from prior to the February 22, 2019 DJO acquisition date, which are not included in Colfax’s Form 10-K reports. Additionally, all Medical Technology segment sales within twelve months of the February 22, 2019 acquisition date were included in the Acquisitions line item of the change in sales reconciliation on the Company’s Form 10-K filings.

(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price and volume.

(3) Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.

(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
## Non-GAAP Reconciliation

### $ millions

<table>
<thead>
<tr>
<th>Notes</th>
<th>Year Ended December 31,</th>
<th>(\text{Notes:})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019</td>
<td>2020</td>
</tr>
<tr>
<td>Net sales</td>
<td>1,080.4</td>
<td>1,120.7</td>
</tr>
<tr>
<td>Pro forma for acquisitions</td>
<td>(1) 169.2</td>
<td>89.9</td>
</tr>
<tr>
<td>Pro forma Net sales</td>
<td>1,249.6</td>
<td>1,120.7</td>
</tr>
<tr>
<td>Acquisitions</td>
<td>(6) (236.4)</td>
<td></td>
</tr>
<tr>
<td>Net sales excluding acquisitions</td>
<td>1,279.7</td>
<td></td>
</tr>
<tr>
<td>Operating income (loss)</td>
<td>45.5</td>
<td>(1.2)</td>
</tr>
<tr>
<td>Restructuring and other related charges</td>
<td>(2) 50.7</td>
<td>23.4</td>
</tr>
<tr>
<td>MDR and other costs</td>
<td>(3) 6.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Strategic transaction costs</td>
<td>(5) 3.8</td>
<td></td>
</tr>
<tr>
<td>Acquisition-related amortization &amp; other non-cash charges</td>
<td>(4) 102.9</td>
<td>107.6</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td>49.0</td>
<td>64.6</td>
</tr>
<tr>
<td>Colfax reported corporate costs</td>
<td>(58.8)</td>
<td>(56.7)</td>
</tr>
<tr>
<td>Corporate costs harmonized with 2021 levels</td>
<td>(14.6)</td>
<td>(16.7)</td>
</tr>
<tr>
<td>Stock compensation costs</td>
<td>16.5</td>
<td>22.5</td>
</tr>
<tr>
<td>Stock compensation costs harmonized with 2021 levels</td>
<td>9.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>200.4</td>
<td>153.6</td>
</tr>
<tr>
<td>Pro forma acquisitions</td>
<td>(1) 23.5</td>
<td>9.2</td>
</tr>
<tr>
<td>Enovis pro forma</td>
<td>223.9</td>
<td>153.6</td>
</tr>
<tr>
<td>Acquisitions</td>
<td>(6) (22.3)</td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA excluding acquisitions</td>
<td>193.4</td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA margins</td>
<td>13.7%</td>
<td>14.5%</td>
</tr>
<tr>
<td>Pro forma adjusted EBITDA margins</td>
<td>17.9%</td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA margins excluding acquisitions</td>
<td>15.1%</td>
<td></td>
</tr>
</tbody>
</table>

Note: Dollars in millions. Some periods may not foot due to rounding.
## Non-GAAP Reconciliation

### $ millions

<table>
<thead>
<tr>
<th></th>
<th>Fabrication Technology</th>
<th>Year Ended December 31</th>
<th>2015</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td></td>
<td></td>
<td>$1,585.2</td>
<td>$2,428.1</td>
</tr>
<tr>
<td>Operating income (GAAP)</td>
<td></td>
<td></td>
<td>168.7</td>
<td>337.4</td>
</tr>
<tr>
<td>Restructuring and other related charges</td>
<td></td>
<td></td>
<td>29.7</td>
<td>19.0</td>
</tr>
<tr>
<td>Intangible asset impairment charge</td>
<td></td>
<td></td>
<td>1.5</td>
<td>-</td>
</tr>
<tr>
<td>Strategic transaction costs</td>
<td></td>
<td></td>
<td>-</td>
<td>2.9</td>
</tr>
<tr>
<td>Acquisition-related amortization and other non-cash charges</td>
<td></td>
<td></td>
<td>29.4</td>
<td>35.9</td>
</tr>
<tr>
<td>Depreciation and other amortization</td>
<td></td>
<td></td>
<td>45.6</td>
<td>38.5</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
<td></td>
<td></td>
<td>$274.8</td>
<td>$433.6</td>
</tr>
</tbody>
</table>

(1) Includes costs related to the planned separation.

(2) Includes amortization of acquired intangibles and fair value charges on acquired inventory.